XELOX和OLF方案治疗晚期胃癌的临床研究  

A Clinical Study of XELOX and OLF in the Treatment of Advanced Gastric Cancer

作　　者：杜春[1] 陈春华[1] 

机构地区：[1]内蒙古医学院附属医院消化内科,内蒙古呼和浩特010050

出　　处：《内蒙古医学杂志》2010年第3期260-263,共4页Inner Mongolia Medical Journal

摘　　要：目的：比较XELOX和OLF方案治疗晚期胃癌患者的近期疗效、临床获益反应、疾病无进展时间及毒副反应。方法：XELOX组：希罗达（Xeloda）1 000 mg/（m^2.d）,2次/d,餐后口服,1-14 d;奥沙利铂（L-OHP）130 mg/m^2,静脉滴注2 h/d,每3周为1个周期。OLF组：奥沙利铂（L-OHP）130 mg/m^2,静脉滴注2 h/d;亚叶酸钙（CF）200 mg/m^2,静脉滴注2 h,1-5 d;5-氟脲嘧啶（5-FU）500 mg/m^2,静脉滴注6 h,1-5 d,每3周为1个周期。结果：XELOX组中位无进展期（medianti me to progress,mTTP）6个月,OLF组mTTP 5个月,总体1年生存率44.0%（11/25）。无化疗相关性死亡。结论：XELOX和OLF方案在相同条件下治疗晚期胃腺癌疗效确切,接近毒副作用可以耐受,安全性好。XELOX方案用药更方便,且在复治患者中可能更有优势。Objective：To observe the efficacy,clinical benefit response,time to no progress and adverse effect of XELOX and OLF for the preoperated patients with advanced gastric cancer.Methods： XELOX group： capecitabine 1000 mg/m^2/d,twice a day,po for 14days,oxaliplatin 130 mg/m^2,intravenous infusion d1,every three weeks.OLF group： Oxaliplatin 130 mg/m^2,intravenous infusion d1,calcium folinate200 mg/m^2,intravenous infusion 1-5d,5-fluorouracil 500 mg/m^2,intravenous infusion 1-5d,every three weeks.Results： The median time to progress（mTTP） in the XELOX group was 6 months,and mTTP in the OLF group was 5 months,the survival of one year rate was 44.0%（11/25）.All the patients were safety.Conclusions： The XELOX and OLF is effective in the treatment of patients with advanced gastric cancer under the same conditions.XELOX programs may be more convenient,and may be more advantage in the re-treated patients.

关 键 词：晚期胃癌 联合化疗 

分 类 号：R735.2[医药卫生—肿瘤]